Phase I BI907828 in advanced TP53WT MDM2 amplified
Research payments
$1,456,844
Through program year 2023, $1,456,844 in research payments was reported against Phase I BI907828 in advanced TP53WT MDM2 amplified, across 33 payments.
- Paid by (largest first)
- Boehringer Ingelheim Pharmaceuticals, Inc.; Boehringer Ingelheim Pharma GmbH & Co.KG
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
2 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2023 | Research | $1,371,630 | 25 |
| 2022 | Research | $85,214 | 8 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
8 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Sant Chawla Santa Monica, CA Named on 7 payments
- Anthony Shields Detroit, MI Named on 4 payments
- Ilyas Sahin Gainesville, FL Named on 4 payments
- Jeremy Kratz Madison, WI Named on 4 payments
- Neeta Somaiah Houston, TX Named on 4 payments
- Andrew Sochacki Grand Rapids, MI Named on 3 payments
- Michael Pishvaian Washington, DC Named on 2 payments
- Jaspreet Grewal Louisville, KY Named on 2 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.